MedTrace Logo

Hypertonic Saline (6%) Versus Isotonic Saline (0.9%) in Bronchiectasis

NCT01112410 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2010-04-28

No results posted yet for this study

Summary

The investigators hypothesise that nebulised hypertonic saline (6%) will increase the volume of sputum expectorated over a 24 hour period compared to nebulised isotonic saline (0.9%) in patients with mild to severe stable bronchiectasis.

Conditions

Interventions

OTHER

Hypertonic saline

Hypertonic saline (6%) nebulised twice a day for 4 weeks. (Randomised crossover trial)

OTHER

Isotonic saline

Isotonic Saline (0.9%) nebulised twice a day for 4 weeks.

Sponsors & Collaborators

  • Belfast Health and Social Care Trust

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-01-31
Primary Completion
2010-08-31
Completion
2010-08-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01112410 on ClinicalTrials.gov